JP2014509593A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014509593A5 JP2014509593A5 JP2013558187A JP2013558187A JP2014509593A5 JP 2014509593 A5 JP2014509593 A5 JP 2014509593A5 JP 2013558187 A JP2013558187 A JP 2013558187A JP 2013558187 A JP2013558187 A JP 2013558187A JP 2014509593 A5 JP2014509593 A5 JP 2014509593A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- pharmaceutical composition
- erbb3
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161452974P | 2011-03-15 | 2011-03-15 | |
| US201161452976P | 2011-03-15 | 2011-03-15 | |
| US61/452,976 | 2011-03-15 | ||
| US61/452,974 | 2011-03-15 | ||
| PCT/US2012/029292 WO2012125864A2 (en) | 2011-03-15 | 2012-03-15 | Overcoming resistance to erbb pathway inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014509593A JP2014509593A (ja) | 2014-04-21 |
| JP2014509593A5 true JP2014509593A5 (enExample) | 2014-06-19 |
Family
ID=45953230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013558187A Withdrawn JP2014509593A (ja) | 2011-03-15 | 2012-03-15 | ＥｒｂＢ経路阻害剤に対する耐性の克服 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150231238A1 (enExample) |
| EP (2) | EP2686015A2 (enExample) |
| JP (1) | JP2014509593A (enExample) |
| KR (1) | KR20140023921A (enExample) |
| CN (1) | CN103429262A (enExample) |
| AU (1) | AU2012229062A1 (enExample) |
| BR (1) | BR112013022887A2 (enExample) |
| CA (1) | CA2828043A1 (enExample) |
| EA (1) | EA201301025A1 (enExample) |
| IL (1) | IL228393A0 (enExample) |
| MX (1) | MX2013010444A (enExample) |
| SG (1) | SG192775A1 (enExample) |
| WO (1) | WO2012125864A2 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2129396T3 (pl) * | 2007-02-16 | 2014-02-28 | Merrimack Pharmaceuticals Inc | Przeciwciała przeciw ERBB3 i ich zastosowania |
| US8895001B2 (en) | 2010-03-11 | 2014-11-25 | Merrimack Pharmaceuticals, Inc. | Use of ErbB3 inhibitors in the treatment of triple negative and basal-like breast cancers |
| US8691231B2 (en) | 2011-06-03 | 2014-04-08 | Merrimack Pharmaceuticals, Inc. | Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies |
| AU2012318541B2 (en) * | 2011-10-06 | 2018-04-12 | Aveo Pharmaceuticals, Inc. | Predicting tumor response to anti-ERBB3 antibodies |
| AU2012340766B2 (en) | 2011-11-23 | 2018-05-10 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
| WO2013110030A2 (en) * | 2012-01-19 | 2013-07-25 | Duke University | Vaccines against antigens involved in therapy resistance and methods of using same |
| US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
| US11305012B2 (en) * | 2013-09-24 | 2022-04-19 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
| WO2015066543A1 (en) * | 2013-11-01 | 2015-05-07 | Board Of Regents, The University Of Texas System | Targeting her2 and her3 with bispecific antibodies in cancerous cells |
| WO2015100459A2 (en) | 2013-12-27 | 2015-07-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| HRP20250041T1 (hr) * | 2014-02-28 | 2025-03-14 | Merus N.V. | Antitijelo koje veže erbb-2 i erbb-3 |
| ES2816624T3 (es) | 2014-02-28 | 2021-04-05 | Merus Nv | Anticuerpos que se unen a EGFR y ERBB3 |
| US10745490B2 (en) | 2014-04-11 | 2020-08-18 | Celldex Therapeutics, Inc. | Anti-ErbB antibodies and methods of use thereof |
| CA2944892A1 (en) * | 2014-05-14 | 2015-11-19 | F. Hoffmann-La Roche Ag | Her3/her2 bispecific antibodies binding to the beta-hairpin of her3 and domain ii of her2 |
| MA39599A (fr) | 2014-05-14 | 2016-10-05 | Merrimack Pharmaceuticals Inc | Dosage et administration d'agents thérapeutiques anti-egfr |
| WO2016007504A1 (en) | 2014-07-07 | 2016-01-14 | Duke University | Vaccines against an oncogenic isoform of esr1 and methods of using the same |
| WO2016007499A1 (en) | 2014-07-07 | 2016-01-14 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
| US10526416B2 (en) | 2014-09-08 | 2020-01-07 | Yeda Research And Development Co. Ltd. | Anti-HER3 antibodies and uses of same |
| JP2017534574A (ja) | 2014-09-08 | 2017-11-24 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドＹｅｄａ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏ．Ｌｔｄ． | チロシンキナーゼ阻害薬（ｔｋｉ）に耐性のがんを処置するための組成物および方法 |
| MA45420A (fr) * | 2015-04-17 | 2019-05-01 | Merrimack Pharmaceuticals Inc | Traitements combinés avec seribantumab |
| JP6542468B2 (ja) | 2015-05-01 | 2019-07-10 | ウー アンドリュー マン チュン | Ｐｉｎｋ１のｃ末端ドメインポリペプチドおよびそれを癌治療に使用する方法 |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
| WO2017035482A1 (en) * | 2015-08-27 | 2017-03-02 | Merrimack Pharmaceuticals, Inc | Combination therapies for treatment of heregulin positive cancers |
| KR20250157457A (ko) | 2015-10-23 | 2025-11-04 | 메뤼스 엔.페. | 암 성장을 억제하는 결합 분자 |
| EP3176183A1 (en) | 2015-12-02 | 2017-06-07 | Yeda Research and Development Co. Ltd | Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki) |
| CN108697779B (zh) | 2016-01-07 | 2023-09-19 | 杜克大学 | 癌症疫苗和递送方法 |
| US11224665B2 (en) | 2016-10-05 | 2022-01-18 | Duke University | Mitochondrial antiviral signaling (MAVS) protein compositions and methods of using the same |
| US10487143B2 (en) | 2016-10-05 | 2019-11-26 | Duke University | Vaccines against HER3 antigens and methods of using the same |
| WO2018182422A1 (en) | 2017-03-31 | 2018-10-04 | Merus N.V. | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene |
| CN111148764B (zh) | 2017-05-17 | 2025-08-12 | 美勒斯公司 | 用于乳腺癌的ErbB-2/ErbB-3双特异性抗体与内分泌治疗的组合 |
| PL3665198T3 (pl) | 2017-08-09 | 2025-06-09 | Merus N.V. | Przeciwciała wiążące egfr i cmet |
| WO2019088348A1 (ko) * | 2017-11-06 | 2019-05-09 | 한국과학기술원 | Egfr 저해제 저항성 암 치료제 |
| AU2020371040B2 (en) * | 2019-10-24 | 2025-10-09 | Merus B.V. | Means and methods for treating subjects with HER2 and HER3 positive cancer |
| KR20240101682A9 (ko) | 2021-11-15 | 2025-12-10 | 시스트이뮨, 인코포레이티드 | 이중특이 항체-캄프토테신 약물 접합체 및 이의 약학적 용도 |
| AR127893A1 (es) * | 2021-12-10 | 2024-03-06 | Servier Lab | Terapia del cáncer dirigida a egfr |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| US7390632B2 (en) | 1999-09-30 | 2008-06-24 | Tumor Biology Investment Group, Inc. | Soluble ErbB3 receptor isoforms |
| US7612042B2 (en) | 2001-05-31 | 2009-11-03 | Tumor Biology Investment Group, Inc. | Methods for inhibiting heregulin and treating cancer |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| AU2003218600C1 (en) | 2002-03-26 | 2009-12-17 | Zensun (Shanghai) Science & Technology Co., Ltd. | ERBB3 based methods and compositions for treating neoplasms |
| US7332580B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The University Of California | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| PL2129396T3 (pl) | 2007-02-16 | 2014-02-28 | Merrimack Pharmaceuticals Inc | Przeciwciała przeciw ERBB3 i ich zastosowania |
| MX338151B (es) | 2007-03-01 | 2016-04-05 | Symphogen As | Composiciones de anticuerpo recombinante anti-receptor de factor de crecimiento epidermico. |
| NZ581201A (en) | 2007-05-11 | 2012-05-25 | Enzon Pharmaceuticals Inc | Rna antagonist compounds for the modulation of her3 |
| EA022201B1 (ru) | 2008-04-11 | 2015-11-30 | Мерримак Фармасьютикалз, Инк. | Агент, способный связываться с опухолевой клеткой, содержащий линкер на основе hsa, и его применение |
| JP5677972B2 (ja) | 2008-11-18 | 2015-02-25 | メリマック ファーマシューティカルズ インコーポレーティッド | ヒト血清アルブミンリンカーおよびそのコンジュゲート |
| NZ594665A (en) * | 2009-03-20 | 2013-08-30 | Genentech Inc | Bispecific anti-her antibodies |
| AU2010242914B2 (en) | 2009-04-29 | 2014-11-13 | Trellis Bioscience, Llc | Improved antibodies immunoreactive with heregulin-coupled HER3 |
| CA2782571C (en) | 2009-12-22 | 2018-01-23 | Roche Glycart Ag | Anti-her3 antibodies and uses thereof |
| BR112012025730B1 (pt) | 2010-04-09 | 2020-12-08 | Aveo Pharmaceuticals, Inc | anticorpo isolado que se liga ao erbb3 humano, seus usos, seu processo de produção e vetor de expressão |
| EP3156421B1 (en) * | 2010-11-01 | 2018-06-06 | Symphogen A/S | Pan-her antibody composition |
| WO2012116317A2 (en) * | 2011-02-24 | 2012-08-30 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-erbb3 agents |
-
2012
- 2012-03-15 US US14/004,848 patent/US20150231238A1/en not_active Abandoned
- 2012-03-15 CA CA2828043A patent/CA2828043A1/en not_active Abandoned
- 2012-03-15 JP JP2013558187A patent/JP2014509593A/ja not_active Withdrawn
- 2012-03-15 WO PCT/US2012/029292 patent/WO2012125864A2/en not_active Ceased
- 2012-03-15 BR BR112013022887A patent/BR112013022887A2/pt not_active IP Right Cessation
- 2012-03-15 EP EP12714108.3A patent/EP2686015A2/en not_active Withdrawn
- 2012-03-15 KR KR1020137026522A patent/KR20140023921A/ko not_active Withdrawn
- 2012-03-15 SG SG2013061791A patent/SG192775A1/en unknown
- 2012-03-15 EP EP14166702.2A patent/EP2815765A1/en not_active Withdrawn
- 2012-03-15 AU AU2012229062A patent/AU2012229062A1/en not_active Abandoned
- 2012-03-15 CN CN201280011820XA patent/CN103429262A/zh active Pending
- 2012-03-15 MX MX2013010444A patent/MX2013010444A/es unknown
- 2012-03-15 EA EA201301025A patent/EA201301025A1/ru unknown
-
2013
- 2013-09-12 IL IL228393A patent/IL228393A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014509593A5 (enExample) | ||
| JP2013522237A5 (enExample) | ||
| CN102812045B (zh) | 用于治疗或预防人表皮生长因子受体‑3(her‑3)相关疾病的材料和方法 | |
| JP2024037894A5 (enExample) | ||
| JP2018052959A5 (enExample) | ||
| US20150231238A1 (en) | Overcoming resistance to erbb pathway inhibitors | |
| JP2013537546A5 (enExample) | ||
| JP2015500828A5 (enExample) | ||
| JP2015517300A5 (enExample) | ||
| JP2017514795A5 (enExample) | ||
| JP2016166203A5 (enExample) | ||
| JP2017529838A5 (enExample) | ||
| HRP20170462T1 (hr) | Protutijela za epidermalni receptor 3 faktora rasta (her3) | |
| EP3603672A1 (en) | Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof | |
| JP2010523536A5 (enExample) | ||
| CA2872226A1 (en) | Humanized pan-her antibody compositions | |
| AU2013201584A1 (en) | Methods for treating pancreatic cancer using combination therapies comprising an anti-ErbB3 antibody | |
| US20200308286A1 (en) | Methods, compositions, and kits for treatment of cancer | |
| JP2017534574A (ja) | チロシンキナーゼ阻害薬（ｔｋｉ）に耐性のがんを処置するための組成物および方法 | |
| RU2012151889A (ru) | Применение имидазохинолинов для лечения заболеваний, зависимых от egfr, или заболеваний с приобретенной резистентностью к агентам, которые связываются с членами семейства egfr | |
| WO2012154587A2 (en) | Methods for preventing toxic drug-drug interactions in combination therapies comprising anti-erbb3 agents | |
| US20240398943A1 (en) | Methods of treating cancer and the pharmaceutical compositions thereof | |
| US20250215087A1 (en) | Combination therapy of kras inhibitor and treg depleting agent | |
| JP2017515843A5 (enExample) | ||
| CN113747897B (zh) | 喹啉衍生物与抗体联合治疗软组织肉瘤 |